Roth Capital Comments on Bio-Path Holdings, Inc.’s FY2028 Earnings (NASDAQ:BPTH)

Bio-Path Holdings, Inc. (NASDAQ:BPTHFree Report) – Equities research analysts at Roth Capital issued their FY2028 earnings estimates for Bio-Path in a research note issued to investors on Tuesday, April 2nd. Roth Capital analyst J. Aschoff expects that the company will post earnings of $42.92 per share for the year. The consensus estimate for Bio-Path’s current full-year earnings is ($20.80) per share.

A number of other equities research analysts have also issued reports on BPTH. Roth Mkm upped their target price on Bio-Path from $12.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 27th. StockNews.com started coverage on Bio-Path in a report on Sunday. They set a “sell” rating on the stock.

Get Our Latest Analysis on BPTH

Bio-Path Stock Performance

BPTH opened at $4.03 on Thursday. Bio-Path has a 1-year low of $3.51 and a 1-year high of $44.80. The stock’s 50 day simple moving average is $6.67 and its 200 day simple moving average is $8.85.

Bio-Path (NASDAQ:BPTHGet Free Report) last issued its earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting the consensus estimate of ($5.40). During the same quarter in the previous year, the business earned ($10.60) EPS.

Institutional Investors Weigh In On Bio-Path

A number of institutional investors have recently bought and sold shares of BPTH. Vanguard Group Inc. grew its position in Bio-Path by 77.5% during the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after acquiring an additional 117,914 shares during the period. Walleye Capital LLC acquired a new stake in Bio-Path during the 3rd quarter worth approximately $77,000. Renaissance Technologies LLC purchased a new position in Bio-Path in the second quarter valued at approximately $70,000. Virtu Financial LLC acquired a new position in Bio-Path during the first quarter valued at approximately $38,000. Finally, Citadel Advisors LLC purchased a new stake in Bio-Path during the third quarter worth approximately $35,000. 5.74% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Path Company Profile

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Articles

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.